1HCWB : What's Going On With HCW Biologics Stock Monday?
HCW Biologics shares are trading higher on Monday after the company announced clearance from the Food and Drug Administration ...
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
Wong, Founder and CEO of HCW Biologics, commented, “The FDA’s clearance to initiate our first-in-human clinical trial for HCW9302 brings us one step closer to advancing a potentially transformative ...
FDA approves HCW Biologics trial for alopecia treatment
MIRAMAR, Fla. - HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company with a market capitalization of approximately $12.4 million, announced today that it has received U.S.
Pharmabiz6d
HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata
HCW Biologics gets US FDA nod to begin first-in-human phase 1 trial of HCW9302 to treat patients with moderate-to-severe alopecia areata: Miramar, Florida Wednesday, February 5, 2 ...
HCW Biologics receives clearance of IND from FDA for HCW9302
HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...
HCWB stock touches 52-week low at $0.25 amid market challenges
HCW Biologics Inc. shares have reached a new 52-week low, trading at $0.25, as the company faces a challenging market environment. According to InvestingPro data, the company's financial health score ...
Pharma company granted FDA clearance for alopecia drug study
The goal is to find a cure for alopecia areata, an autoimmune disease that causes hair loss in distinct round patches.
Morningstar8d
HCW Biologics Granted FDA Clearance to Evaluate One of the Company’s Lead Product Candidates in a First-In-Human Phase 1 Clinical Trial
MIRAMAR, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (“HCWB” or the “Company”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical ...